Tuesday, January 31, 2023 1:08:12 PM
https://www.takeda.com/newsroom/newsreleases/2022/takedas-biologics-license-application-bla-for-dengue-vaccine-candidate-tak-003-granted-priority-review-by-us-food-and-drug-administration
4 months or less until an answer. Expedited review is six months or less now. It was accepted Nov 22nd.
Big if we get FDA apprvoval. ETF's in the know are sucking up shares.
Other approved drug has serious side effects vs. ours.
300M cases a year from mosquito bites.
Boing X 2
Recent TAK News
- Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer • Business Wire • 04/26/2024 12:30:00 PM
- HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda • GlobeNewswire Inc. • 04/26/2024 12:30:00 PM
- Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder • PR Newswire (US) • 04/23/2024 11:00:00 AM
- Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs • PR Newswire (US) • 04/22/2024 08:10:00 AM
- U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease • Business Wire • 04/18/2024 11:00:00 PM
- Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food • Business Wire • 04/08/2024 12:00:00 PM
- Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE • PR Newswire (US) • 03/27/2024 12:56:00 PM
- Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE • PR Newswire (US) • 03/27/2024 12:53:00 PM
- Takeda annonce les candidats au conseil d’administration pour la prochaine assemblée générale des actionnaires • Business Wire • 03/27/2024 05:01:00 AM
- Takeda gibt Kandidaten für den Vorstand bei der kommenden Aktionärsversammlung bekannt • Business Wire • 03/27/2024 05:01:00 AM
- Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting • Business Wire • 03/26/2024 11:07:00 PM
- 第148回定時株主総会に提案する取締役候補者について • Business Wire • 03/26/2024 11:07:00 PM
- Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP) • Business Wire • 03/26/2024 12:00:00 PM
- 武田薬品、Ph+ ALLの初発成人患者に対するアイクルシグ®(ポナチニブ)の医薬品承認事項変更申請(sNDA)について、FDAからの承認取得を発表 • Business Wire • 03/21/2024 01:39:00 PM
- Takeda meldet sNDA-Zulassung von ICLUSIG® (Ponatinib) durch die FDA bei erwachsenen Patienten mit neu diagnostizierter Ph+ ALL • Business Wire • 03/21/2024 07:33:00 AM
- Takeda annonce l'approbation par la FDA des États-Unis d'une demande supplémentaire de nouveau médicament (sNDA) pour ICLUSIG ® (ponatinib) chez les patients adultes atteints de leucémie lymphoblastique aiguë (LAL Ph+) nouvellement diagnostiquée • Business Wire • 03/20/2024 07:18:00 PM
- Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL • Business Wire • 03/19/2024 04:20:00 PM
- CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders • GlobeNewswire Inc. • 03/19/2024 10:30:54 AM
- Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia • Business Wire • 03/13/2024 12:00:00 PM
- 武田薬品とBiological E. Limited、デング熱流行地域におけるワクチンへのアクセス促進で協力 • Business Wire • 02/28/2024 12:03:00 PM
- Takeda et Biological E. Limited s’associent pour accélérer l’accès au vaccin contre la dengue dans les zones endémiques • Business Wire • 02/27/2024 10:26:00 PM
- Takeda und Biological E. Limited arbeiten zusammen, um den Zugang zu Dengue-Impfstoff in endemischen Gebieten zu beschleunigen • Business Wire • 02/27/2024 12:38:00 PM
- Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas • Business Wire • 02/27/2024 04:30:00 AM
- Championing Rare Voices on Rare Disease Day • PR Newswire (Canada) • 02/26/2024 12:00:00 PM
- Faire entendre sa voix à l'occasion de la Journée des maladies rares • PR Newswire (Canada) • 02/26/2024 12:00:00 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM